Dr. Sheridan is a principal in the Intellectual Property Practice at Charles River Associates. He has addressed a broad range of financial and economic issues in the context of litigation, including lost profits, unjust enrichment, reasonable royalty, commercial success, irreparable harm, and the economic prong of the domestic industry requirement in Section 337 ITC matters. The engagements he has worked on span a wide range of industries, and include pharmaceuticals, biologics, diagnostics and medical devices. Previously, Dr. Sheridan was as an assistant director at the technology transfer office at the University of Chicago, where he worked for five years, focusing primarily on the commercialization of early stage technologies.  Dr. Sheridan was named to the IAM Patent 1000: The World’s Leading Patent Professionals (economic experts) in 2019.

Eberle Schultz is a Counsel at O’Melveny & Myers where she practices complex patent litigation within the biotechnology, pharmaceutical, and chemical industries.  Eberle counsels life sciences clients in all aspects of patent litigation to help businesses achieve their strategic goals.

Eberle represents innovator pharmaceutical companies in patent ligation under the Hatch-Waxman Act and is experienced in innovator declaratory judgement actions, inter partes review proceedings before the Patent Trial and Appeal Board, Federal Circuit appeals, licensing disputes, and patent validity opinions.  She has litigated a variety of technologies, including multiple anti-cancer therapies and biologics.